Insulin receptor substrate-2 (989-1007)

Insulin receptor substrate-2 (989-1007) is a synthetic peptide fragment corresponding to amino acids 989 through 1007 of the IRS-2 protein, a critical adaptor molecule in insulin and insulin-like growth factor signaling pathways. As a peptide compound, it serves as a valuable molecular tool for dissecting the functional domains of IRS-2, which is integral to cellular responses such as glucose metabolism, growth, and differentiation. Its defined sequence enables researchers to investigate site-specific interactions, post-translational modifications, and the mechanistic underpinnings of insulin signaling cascades in various biological contexts. The use of this peptide fragment supports advanced studies in metabolic regulation, signal transduction, and the molecular basis of insulin resistance.

Signal transduction studies: Researchers frequently utilize this IRS-2-derived peptide to probe the molecular mechanisms of insulin receptor signaling. By mimicking a specific region of the full-length protein, the peptide enables detailed mapping of phosphorylation sites and interaction motifs that mediate downstream signaling events. Such investigations are pivotal for elucidating how IRS-2 transmits signals from activated insulin receptors to intracellular effector proteins, thereby advancing the understanding of metabolic regulation at the molecular level.

Kinase substrate assays: The peptide fragment is widely employed as a substrate in kinase activity assays, particularly for tyrosine kinases such as the insulin receptor. Its defined amino acid sequence allows for precise assessment of kinase specificity, activity, and regulatory mechanisms in vitro. By quantifying phosphorylation events on this peptide, scientists can evaluate the functional consequences of mutations, inhibitors, or activators on the enzymatic activity of insulin receptor kinases, supporting both basic research and early-stage drug discovery efforts.

Protein-protein interaction analysis: The IRS-2 (989-1007) peptide serves as a useful probe for identifying and characterizing binding partners that interact with this region of the parent protein. Through techniques such as pull-down assays, surface plasmon resonance, or fluorescence polarization, researchers can assess the affinity and specificity of interactions between IRS-2 and adaptor proteins, phosphatases, or other signaling molecules. These studies contribute to a more comprehensive understanding of the dynamic protein networks that regulate insulin action and cellular homeostasis.

Antibody production and epitope mapping: The defined sequence of this peptide fragment makes it suitable for generating sequence-specific antibodies or for mapping antigenic epitopes within the IRS-2 protein. Polyclonal or monoclonal antibodies raised against this region can be employed in immunoprecipitation, immunoblotting, or immunofluorescence applications to track IRS-2 localization, expression, or post-translational modifications in cell and tissue samples. Such reagents are essential for dissecting IRS-2 function and for validating experimental models of metabolic signaling.

Peptide-based inhibitor design: The structural and functional information provided by the IRS-2 (989-1007) peptide facilitates the rational design of peptide-based inhibitors or mimetics targeting protein-protein interactions within insulin signaling pathways. By serving as a template for structure-activity relationship studies, the peptide aids in the development of novel molecular tools or lead compounds that selectively modulate IRS-2-mediated signaling events. This approach supports both mechanistic research and the exploration of potential strategies for modulating insulin sensitivity in metabolic research models.

1. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells

2. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review

4. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

5. Cell-based adhesion assays for isolation of snake venom’s integrin antagonists